Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.Cancer Research|August 21, 2023
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug ToleranceJennifer L Cotton, Javier Estrada Diez, Vivek Sagar, et al.Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.Cancer Cell|July 19, 2024
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancerLeslie Duplaquet, Kevin So, Alexander W Ying, et al.Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.Nature Communications|March 12, 2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerMatthew J Niederst, Lecia V Sequist, John T Poirier, et al.Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.Pageof 3